Key information

🔎 Fund Overview

Cullinan Oncology, Inc. is a biopharmaceutical company. The Company is focused on creating standards of care for patients with cancer. The Company’s lead candidate, Zipalertinib (CLN-081/TAS6417) in a Phase IIb, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase IIb trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-418, CLN-617 and CLN-978. Its CLN-049 is a FLT3/CD3 T cell engaging bispecific antibody being investigated in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).